Obinutuzumab-Induced Inflammatory Bowel Disease-Like Pancolitis: A First Case Report
Introduction: Obinutuzumab is a type II anti-CD20 monoclonal antibody associated with a higher rate of toxicity when compared to rituximab. Gastrointestinal side-effects have been reported but data is still sparse. Case Presentation: A 47-year-old female with medical history of stage IV follicular n...
Main Authors: | Raquel R. Mendes, Pedro C. Figueiredo, Isabel Andrade |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2023-09-01
|
Series: | GE: Portuguese Journal of Gastroenterology |
Subjects: | |
Online Access: | https://beta.karger.com/Article/FullText/533499 |
Similar Items
-
The Acquisition of Complement-Dependent Cytotoxicity by the Type II Anti-CD20 Therapeutic Antibody Obinutuzumab
by: Alicja Kuźniewska, et al.
Published: (2023-12-01) -
Acute Thrombocytopenia Complicating the Initial Administration of Obinutuzumab: Is It More Frequent Than We Think?
by: Umut Yılmaz, et al.
Published: (2024-01-01) -
Disseminated Enterovirus Infection in a Patient Affected by Follicular Lymphoma Treated with Obinutuzumab: A Case Report and a Narrative Review of the Literature
by: Tommaso Lupia, et al.
Published: (2024-03-01) -
Safety of a 90-min duration of intravenous infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma in a tertiary hospital in China: a prospective, open-label, exploratory clinical trial
by: Shuangshuang Xing, et al.
Published: (2024-02-01) -
Cost–effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma
by: Jun Ma, et al.
Published: (2023-11-01)